The effect of HAART on humoral immune response in primary HIV-1 infected patients

Claudia Pastori, C. Barassi, F. Lillo, R. Longhi, B. Capiluppi, S. Nozza, A. Galli, C. Uberti-Foppa, A. Lazzarin, G. Tambussi, L. Lopalco

Research output: Contribution to journalArticlepeer-review


The effect of Highly Active Antiretroviral Therapy (HAART) on binding and neutralizing antibody responses to human immunodeficiency virus type-1 (HIV-1) during primary and chronic infection was investigated. Seven patients HAART treated during primary infection, six HAART treated during chronic infection and five patients treated only with ZVD (Zidovudine) were analysed. HAART inhibited the development of anti env antibodies during primary infection. Administering HAART during primary infection usually did not substantially affect the development of weak neutralizing antibody responses against autologous virus. However, we demonstrated that very early treatment, during seroconversion, induce in some cases, a strong neutralizing antibodies against autologous virus. These results may be relevant for understanding how HAART may elicit a strong protective responses and may be useful in developing new strategies designed to achieve a long term control of the HIV infection.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number1
Publication statusPublished - 2002


  • HIV-1
  • Humoral immunity
  • Neutralizing antibodies
  • PHI

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)


Dive into the research topics of 'The effect of HAART on humoral immune response in primary HIV-1 infected patients'. Together they form a unique fingerprint.

Cite this